Cara Therapeutics Inc

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors. Its lead product candidate includes intravenous CR845, which has completed Phase 2 clinical trials for the treatment acute postoperative pain in adult patients, as well as in Phase 2 clinical…More trials for the treatment of uremic pruritus disease.